Chance Pharma和华东医学合作伙伴在中国推出哮喘药物CXG87,预期于2026年初获得批准。 Chance Pharma and Huadong Medicine partner to launch asthma drug CXG87 in China, with approval expected in early 2026.

Chance Pharma与华东医药公司合作,将其在中国大陆的呼吸道药物CXG87商业化。 CXG87是一种2.2级新药物,旨在治疗哮喘,改善呼吸困难患者的可用性。 Chance Pharma has partnered with Huadong Medicine to commercialize its respiratory drug CXG87 in mainland China, a Class 2.2 new drug designed to treat asthma with improved usability for patients with weak breathing. 这种药物是布德胺/格醇的增强版,其流量依赖性较低,并且使用简单的单剂量吸入器来减少用户错误. The drug, an enhanced version of budesonide/formoterol, features lower flow rate dependency and a simple, single-dose inhaler to reduce user error. 中国的第三阶段临床试验入学率已经完成,预计2026年初将有一项新的药物应用。 Phase III clinical trial enrollment in China is complete, with a new drug application expected in early 2026. Chance Pharma将管理研发、注册、制造和供应,作为销售授权持有人,而华东医药公司将利用其国家销售网络带头进行商业化。 Chance Pharma will manage R&D, registration, manufacturing, and supply as the Marketing Authorization Holder, while Huadong Medicine will lead commercialization using its national sales network. 这笔交易包括预付和里程碑付款,加上今后的利润分享。 The deal includes upfront and milestone payments, plus future profit sharing.